Table 3.
HbA1c, C-peptide, lipid profile, atherogenic potential and C-reactive protein for Active treatment and Placebo at baseline and week 12.
| Test * | Group | Baseline Mean ± SD |
p Value | Week 12 Mean ± SD |
p Value | Effect Size | 95% CI |
|---|---|---|---|---|---|---|---|
| HbA1c % (<6.0%) |
Active Placebo |
6.03 ± 0.75 5.83 ± 0.58 |
0.150 | 5.93 ± 0.78 5.75 ± 0.69 |
0.410 | −0.250 | −0.850–0.343 |
| HbA1c mmol/L (<42 mmol/mol) |
Active Placebo |
42.48 ± 8.13 40.00 ± 6.35 |
0.130 | 41.70 ± 8.33 39.60 ± 7.72 |
0.370 | −0.260 | −0.861–0.343 |
| C-peptide (0.8–1.9 µg/L) |
Active Placebo |
0.92 ± 0.36 0.79 ± 0.27 |
0.075 | 0.78 ± 0.25 0.81 ± 0.30 |
0.792 | 0.082 | −0.518–0.681 |
| Cholesterol (3.6–6.9 mmol/L) |
Active Placebo |
5.31 ± 1.15 5.51 ± 1.29 |
0.564 | 5.21 ± 1.02 5.15 ± 1.53 |
0.875 | −0.047 | −0.613–0.520 |
| High Density Lipoprotein (HDL) (>0.9 mmol/L) | Active Placebo |
1.31 ± 0.31 1.21 ± 0.28 |
0.241 | 1.30 ± 0.36 1.18 ± 0.36 |
0.172 | −0.394 | −0.964–0.180 |
| Low Density Lipoprotein (LDL) (<2.0 mmol/L) |
Active Placebo |
3.14 ± 1.17 3.31 ± 1.29 |
0.643 | 3.08 ± 1.10 3.11 ± 1.15 |
0.917 | 0.030 | −0.536–0.597 |
| Total/HDL ratio | Active Placebo |
4.28 ± 1.14 4.60 ± 0.90 |
0.284 | 4.32 ± 1.13 4.46 ± 0.89 |
0.633 | 0.138 | −0.430–0.704 |
| Triglycerides (0.3–4.0 mmol/L) |
Active Placebo |
1.62 ± 0.88 1.97 ± 1.15 |
0.238 | 1.58 ± 0.76 2.28 ± 1.28 |
0.030 | 0.667 | 0.081–1.246 |
| C-reactive protein (CRP) (<5 mmol/L) |
Active Placebo |
5.56 ± 4.14 5.24 ± 4.41 |
0.797 | 5.34 ± 4.11 5.00 ± 4.59 |
0.789 | −0.078 | −0.644–0.489 |
n = 25 active group, n = 23 placebo group. * Numbers in brackets are healthy reference ranges.